Literature DB >> 12665052

Survivin and apoptosis control.

Dario C Altieri1.   

Abstract

Survivin is a member of the inhibitor of apoptosis (TAP) gene family that exhibits differential expression in nearly all human cancers but not in most normal tissues. Recent progress identified a multifunctional survivin pathway positioned at the interface between mitotic progression and apoptosis inhibition, and required to preserve viability of dividing tumor cells (Altieri, 2001; Andersen and Thor, 2002; Jaattela, 1999). The unique properties of survivin have recently found concrete applications for cancer detection, diagnosis, and outcome prediction. In addition, targeting the survivin pathway may offer new therapeutic prospects to lower a general survival threshold in cancer cells. This chapter will focus on the current developments in the field of survivin and its role in apoptosis regulation and mitotic progression. Current perspectives on exploiting the survivin pathway for cancer diagnosis and treatment will be highlighted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12665052     DOI: 10.1016/s0065-230x(03)88303-3

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  34 in total

1.  Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2.

Authors:  Jian-Guo Qiao; Yu-Qing Zhang; Yu-Chun Yin; Zui Tan
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

2.  Dual FRET molecular beacons for mRNA detection in living cells.

Authors:  Philip J Santangelo; Brent Nix; Andrew Tsourkas; Gang Bao
Journal:  Nucleic Acids Res       Date:  2004-04-14       Impact factor: 16.971

3.  Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.

Authors:  Bing Z Carter; Duncan H Mak; Wendy D Schober; Maria Cabreira-Hansen; Miloslav Beran; Teresa McQueen; Wenjing Chen; Michael Andreeff
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

4.  Survivin, a target to modulate the radiosensitivity of Ewing's sarcoma.

Authors:  B Greve; F Sheikh-Mounessi; B Kemper; I Ernst; M Götte; H T Eich
Journal:  Strahlenther Onkol       Date:  2012-10-10       Impact factor: 3.621

5.  Evaluating the expression level of Survivin gene in different groups of B-cell acute lymphoblastic leukemia patients of Iran.

Authors:  Mahan Mohammadi; Farzane Amirmahani; Kiarash Jamshidi Goharrizi; Rambod Pakzad; Hossein Dolat
Journal:  Mol Biol Rep       Date:  2019-04-30       Impact factor: 2.316

6.  Human cancers overexpress genes that are specific to a variety of normal human tissues.

Authors:  Joseph Lotem; Dvir Netanely; Eytan Domany; Leo Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-08       Impact factor: 11.205

7.  Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.

Authors:  T Iwasa; I Okamoto; K Takezawa; K Yamanaka; T Nakahara; A Kita; H Koutoku; M Sasamata; E Hatashita; Y Yamada; K Kuwata; M Fukuoka; K Nakagawa
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 9.075

8.  Tumor-specific gene expression using the survivin promoter is further increased by hypoxia.

Authors:  L Yang; Z Cao; F Li; D E Post; E G Van Meir; H Zhong; W C Wood
Journal:  Gene Ther       Date:  2004-08       Impact factor: 5.250

9.  Fowlpox-based survivin vaccination for malignant mesothelioma therapy.

Authors:  Pietro Bertino; Maddalena Panigada; Elisa Soprana; Valentina Bianchi; Sabrina Bertilaccio; Francesca Sanvito; Aaron H Rose; Haining Yang; Giovanni Gaudino; Peter R Hoffmann; Antonio Siccardi; Michele Carbone
Journal:  Int J Cancer       Date:  2013-02-25       Impact factor: 7.396

10.  Cotransfection of survivin and CD44v3 short hairpin RNAs affects proliferation, apoptosis, and invasiveness of colorectal cancer.

Authors:  Zhonghong Liu; Yonghang Guo; Juan Li; Jun Xu; Bingrong Liu
Journal:  Dig Dis Sci       Date:  2013-02-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.